SIRI as a biomarker for bladder neoplasm: Utilizing decision curve analysis to evaluate clinical net benefit

Abstract

SIRI is an innovative prognostic indicator and a potential biomarker that can enhance conventional medical pathological evaluation and improve the personalization of clinical treatment strategies for bladder cancer patients following RC.